Company InventisBio Co., Limited

Equities

688382

CNE100005Q22

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for InventisBio Co., Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
8.53 ^CNY	-0.81%		-9.26%	-43.66%

Apr. 29	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.

Number of employees: 221

CNY in Million	2022	Weight	2023	Weight	Delta
Innovative Drugs 100.0 %	0	nan %	186	100.0 %	-

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	0	nan %	186	100.0 %	-

Managers	Title	Age	Since
Yao Lin Wang CEO	Chief Executive Officer	61	13-01-10
Lu Wei Shi DFI	Director of Finance/CFO	39	14-12-31
Ling Zhang CTO	Chief Tech/Sci/R&D Officer	60	17-12-31
Ji fang Weng CTO	Chief Tech/Sci/R&D Officer	43	18-12-31
Dan Dan Ren BRD	Director/Board Member	38	20-11-27
Xing Dai BRD	Director/Board Member	49	14-12-31
Yue Heng Jiang BRD	Director/Board Member	53	17-12-31

Members of the board	Title	Age	Since
Yao Lin Wang CEO	Chief Executive Officer	61	13-01-10
Yi Fu Liu BRD	Director/Board Member	45	23-10-29
Xin Miao Dai BRD	Director/Board Member	61	20-12-08
Yue Heng Jiang BRD	Director/Board Member	53	17-12-31
Xing Dai BRD	Director/Board Member	49	14-12-31
Lu Wei Shi DFI	Director of Finance/CFO	39	14-12-31
Wen Chen BRD	Director/Board Member	56	20-12-08
Dan Dan Ren BRD	Director/Board Member	38	20-11-27
Ji fang Weng CTO	Chief Tech/Sci/R&D Officer	43	18-12-31
Zhi Hui Wang BRD	Director/Board Member	33	Dec. 07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	576,658,841	257,205,222 ( 44.60 %)	0	44.60 %

Name	Equities	%	Valuation
Hillhouse Investment Management Ltd. (Invest) 27.37 %	28,749,939	27.37 %	39 M ¥
GF Fund Management Co., Ltd. 12.63 %	13,268,584	12.63 %	18 M ¥
ICBC Credit Suisse Asset Management Co., Ltd. 10.90 %	11,452,849	10.90 %	15 M ¥
Bank of China Investment Management Co., Ltd. 8.778 %	9,220,975	8.778 %	12 M ¥
Penghua Fund Management Co., Ltd. 7.704 %	8,093,052	7.704 %	11 M ¥
First Seafront Fund Management Co., Ltd. 7.527 %	7,906,933	7.527 %	11 M ¥
Zhonghai Fund Management Co., Ltd. 5.329 %	5,597,683	5.329 %	8 M ¥
Maxwealth Fund Management Co., Ltd. 4.440 %	4,664,058	4.440 %	6 M ¥
Hwabao WP Fund Management Co., Ltd. 4.192 %	4,403,832	4.192 %	6 M ¥
HSBC Jintrust Fund Management Co. Ltd. 3.307 %	3,473,684	3.307 %	5 M ¥

Name	Equities	%	Valuation
LAV Management Co., Ltd. 10.12 %	47,558,248	10.12 %	64 M ¥
OrbiMed Advisors Private Equity 6.118 %	28,749,900	6.118 %	39 M ¥

InventisBio, Co., Ltd.

Room 210, 4, Lane 67 Libing Road

201203, Shanghai

http://www.inventisbio.com

address InventisBio Co., Limited(688382)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.53 CNY

Average target price

18.5 CNY

Spread / Average Target

+116.88%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INVENTISBIO CO., LIMITED	-43.66%	679M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs